B. Braun Medical Inc. Recalls Ceftazidime for Injection USP and Dextrose Injection USP (50 mL), Duplex Container

News
Article

The company is recalling the product because of out-of-specification results for high molecular weight polymers.

Braun Medical Inc. (B. Braun) is voluntarily recalling one lot of 2g Ceftazidime for Injection USP (2g) and Dextrose for Injection USP (50 mL) in a Duplex Container. The recall is being conducted because of test results that exceeded specification limits for high molecular weight polymers (HMWP) in a 19-month stability interval.

According to the company, elevated HMWP levels have resulted in kidney damage and liver problems in animal studies, but the impact on humans is unknown. The company is recalling product out of caution. No adverse events have been reported as of the date of the recall. Adverse events may be reported to FDA through the agency’s MedWatch program.

Ceftazidime for Injection USP and Dextrose Injection USP is a cephalosporin antibacterial used to treat lower respiratory tract infections, skin and skin-structure infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections, and central nervous system infections. According to the press release, “Ceftazidime for Injection USP and Dextrose Injection USP in the DUPLEX Container is a flexible dual-chamber container containing approximately 50 mL of 5% Dextrose Injection in the diluent chamber and ceftazidime in the drug powder chamber. After reconstitution, the concentration is equivalent to 2 g ceftazidime.”

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes